Collectively, we propose that triptolide has an advantage compared with other NRF2 inhibitors in that it downregulates the expression of NRF2 target genes without affecting NRF2, which could be used to treat lung cancer cells regardless of mutation status in the Keap1/Nrf2 pathway. Here, NFE2L2 is linked to lung carcinoma.